

FORM 3**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

OMB APPROVALOMB 3235-
Number: 0104
Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * AUBERTON-HERVE ANDRE-JACQUES	2. Date of Event Requiring Statement (Month/Day/Year) 01/24/2018	3. Issuer Name and Ticker or Trading Symbol Bionik Laboratories Corp. [BNKL]	
(Last) (First) (Middle) C/O BIONIK LABORATORIES CORP., 483 BAY STREET, N105		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	5. If Amendment, Date Original Filed (Month/Day/Year) 06/04/2018
(Street) TORONTO, A6 M5G2C9			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned		

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(1)(2)	09/01/2027	Common Stock	6,107,677	\$ 0.161	I	Shares held through 4A Consulting and Engineering

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
AUBERTON-HERVE ANDRE-JACQUES C/O BIONIK LABORATORIES CORP. 483 BAY STREET, N105 TORONTO, A6 M5G2C9	X			

Signatures

/s/ Andre-Jacques Auberton-Herve 06/15/2018

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

As of June 4, 2018, the Issuer and 4A Consulting and Engineering ("4A") entered into a First Amendment to Equity Compensation Agreement (the "Amendment"), which amended the vesting schedule of the options granted to 4A to purchase 6,107,677 shares of the Issuer's common stock, effective as of January 24, 2018. This Form 3 amendment is being filed to disclose the amended vesting schedule of the options pursuant to the Amendment. Pursuant to the Amendment, one-sixth of the option will be vested and exercisable as of the September 1, 2017 date of grant, and the unvested portion of the option will become vested and exercisable as follows: 100% in 5 equal annual installments on each of the five anniversaries of the date of the issuance of the option.

(1) The option shall be fully vested on the occurrence of any of the following conditions: (a) A Change of Control (as defined in the Company's 2014 Equity Incentive Plan) or (b) upon Andre-Jacques Auberton-Herve, the President of 4A, not being Chairman of the Board of the Issuer for any reason.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.